As Biotechnology businesses, Zosano Pharma Corporation (NASDAQ:ZSAN) and Sesen Bio Inc. (NASDAQ:SESN), are affected by compare. This especially applies to their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zosano Pharma Corporation	N/A	0.00	35.36M	-9.39	0.00
Sesen Bio Inc.	N/A	0.00	33.69M	-0.67	0.00

Table 1 demonstrates Zosano Pharma Corporation and Sesen Bio Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides us Zosano Pharma Corporation and Sesen Bio Inc.’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
Zosano Pharma Corporation	0.00%	-185.2%	-116.3%
Sesen Bio Inc.	0.00%	-85.7%	-33.6%

Risk & Volatility

A beta of 2.77 shows that Zosano Pharma Corporation is 177.00% more volatile than Standard and Poor’s 500. From a competition point of view, Sesen Bio Inc. has a 2.08 beta which is 108.00% more volatile compared to Standard and Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of Zosano Pharma Corporation are 5.4 and 5.4 respectively. Its competitor Sesen Bio Inc.’s Current Ratio is 9.1 and its Quick Ratio is 9.1. Sesen Bio Inc. can pay off short and long-term obligations better than Zosano Pharma Corporation.

Institutional and Insider Ownership

Roughly 53.9% of Zosano Pharma Corporation shares are owned by institutional investors while 45.2% of Sesen Bio Inc. are owned by institutional investors. 1.97% are Zosano Pharma Corporation’s share owned by insiders. Competitively, Sesen Bio Inc. has 6.56% of it’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Zosano Pharma Corporation	-4.91%	105.96%	25.39%	19.51%	-11.36%	128.3%
Sesen Bio Inc.	14.36%	30.32%	-43.45%	-50.26%	2.59%	-33.1%

For the past year Zosano Pharma Corporation had bullish trend while Sesen Bio Inc. had bearish trend.

Summary

Sesen Bio Inc. beats on 5 of the 6 factors Zosano Pharma Corporation.

Zosano Pharma Corporation, a clinical stage pharmaceutical company, develops a proprietary intracutaneous delivery system to administer drugs through the skin for rapid symptom relief to patients. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.